Complete Conference Coverage
In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.
The impact of this treatment on quality of life was not previously reported.
It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.
COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.
Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.
This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.
Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.
Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Hyperthermia Plus Chemotherapy Improves Survival in Soft Tissue Sarcoma
- Survey May Help To Identify Patients With Cancer at Risk of HBV Reactivation
- Fish Consumption and Cancer
- Socioeconomic Status May Preclude Elderly Patients From Receiving Pancreatic Cancer Treatment
- Receptor Agonists With Palonosetron May Reduce Needed Dexamethasone Duration